Alterity Therapeutics Net Debt Growth & History (ATHE)
Alterity Therapeutics's net debt was −$37.1M for fiscal 2026.
View full Alterity Therapeutics company overviewAlterity Therapeutics annual net debt history
| Fiscal year | Period ended | Net debt | Change | Growth |
|---|---|---|---|---|
| 2026 | 2026-06-30 | −$37.1M | −$4.1M | — |
| 2025 | 2025-06-30 | −$33.0M | −$20.5M | — |
| 2024 | 2024-06-30 | −$12.5M | $3.1M | — |
| 2023 | 2023-06-30 | −$15.6M | $19.1M | — |
| 2022 | 2022-06-30 | −$34.7M | −$6.6M | — |
| 2021 | 2021-06-30 | −$28.0M | −$18.9M | — |
| 2020 | 2020-06-30 | −$9.2M | $5.1M | — |
| 2019 | 2019-06-30 | −$14.3M | — | — |
Alterity Therapeutics quarterly net debt
| Fiscal quarter | Period ended | Net debt | Change | YoY change |
|---|---|---|---|---|
| Q4 2026 | 2026-06-30 | −$37.1M | −$4.1M | — |
| Q2 2026 | 2025-12-31 | −$49.1M | −$44.7M | — |
| Q4 2025 | 2025-06-30 | −$33.0M | −$20.5M | — |
| Q2 2025 | 2024-12-31 | −$4.4M | — | — |
| Q4 2024 | 2024-06-30 | −$12.5M | $3.1M | — |
| Q4 2023 | 2023-06-30 | −$15.6M | $19.1M | — |
| Q4 2022 | 2022-06-30 | −$34.7M | −$6.6M | — |
| Q4 2021 | 2021-06-30 | −$28.0M | −$18.9M | — |
| Q4 2020 | 2020-06-30 | −$9.2M | $5.1M | — |
| Q4 2019 | 2019-06-30 | −$14.3M | — | — |
Alterity Therapeutics net debt trends
Over the last five fiscal years, Alterity Therapeutics's net debt decreased from −$28.0M to −$37.1M, a change of −$9.1M. The latest reported quarter, Q4 2026, shows −$37.1M.
What net debt means
Net debt compares a company’s interest-bearing debt with its cash and cash equivalents. Positive net debt means debt exceeds cash, while a negative value indicates the company has more cash than debt on this measure.
How net debt is calculated
TickerStat calculates net debt as total interest-bearing debt minus cash and cash equivalents at the same reporting-period end. Short-term investments are not subtracted because they are not included in the standardized cash series. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Alterity Therapeutics source filings ↗